Bristol-Myers Squibb

Bristol Myers faces $1B+ tax fight after accidental disclosure reveals alleged offshore patents scheme — report
Bristol Myers faces $1B+ tax fight after accidental disclosure reveals alleged offshore patents scheme — report
Endpoints
Bristol-Myers Squibb
taxes
tax evasion
IRS
Flag link:
FDA approves first CAR-T cell therapy for multiple myeloma
FDA approves first CAR-T cell therapy for multiple myeloma
BioPharma Dive
Bristol-Myers Squibb
Bluebird Bio
CAR-T
Multiple Myeloma
Abecma
FDA
Flag link:
Bristol Myers Squibb CEO Caforio collected $20M in 2020 pay amid Celgene integration, pandemic challenges
Bristol Myers Squibb CEO Caforio collected $20M in 2020 pay amid Celgene integration, pandemic challenges
Fierce Pharma
Bristol-Myers Squibb
Giovanni Caforio
Pharma CEOs
executive pay
Flag link:
Immuno-Oncology Treatments Finding Success with Combination Therapies
Immuno-Oncology Treatments Finding Success with Combination Therapies
BioSpace
immuno-oncology
Opdivo
Bristol-Myers Squibb
clinical trials
relatilimab
Ibrance
Flag link:
Bristol Myers, with Breyanzi nod in hand, eyes faster cell therapy production
Bristol Myers, with Breyanzi nod in hand, eyes faster cell therapy production
Fierce Pharma
Bristol-Myers Squibb
cell therapy
Breyanzi
drug manufacturing
Flag link:
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
J&J nabs FDA nod for Ponvory, joining Novartis, Bristol Myers in crowded MS market
Fierce Pharma
JNJ
Ponvory
Novartis
Bristol-Myers Squibb
MS
multiple sclerosis
Flag link:
Bristol Myers Squibb's MS innovation challenge winners tap technology for patients
Bristol Myers Squibb's MS innovation challenge winners tap technology for patients
Fierce Pharma
Bristol-Myers Squibb
innovation
MS
multiple sclerosis
devices
Evolution Devices
aritificial intelligence
Flag link:
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Fierce Pharma
Merck
Keytruda
FDA
small cell lung cancer
Opdivo
Bristol-Myers Squibb
Flag link:
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Bristol Myers scales up cell therapy production with liso-cel nod in hand and another approval maybe on the way
Endpoints
Bristol-Myers Squibb
drug manufacturing
cell therapy
liso-cel
CAR-T
Flag link:
Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Nektar, stung by new investor lawsuit over IL-2 drug, secures $150M for Keytruda combo pivotal trial
Endpoints
Nektar Therapeutics
Bristol-Myers Squibb
NKTR-214
Flag link:
Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label
Bristol-Myers, Sanofi ordered to pay Hawaii $834 million over Plavix warning label
Reuters
Bristol-Myers Squibb
Sanofi
Plavix
Hawaii
deceptive marketing
labeling
Flag link:
Bristol Myers Squibb pens $1.3B biobucks pact with Molecular Templates, axes Celgene CAR-T asset
Bristol Myers Squibb pens $1.3B biobucks pact with Molecular Templates, axes Celgene CAR-T asset
Fierce Biotech
Bristol-Myers Squibb
Molecular Templates
biobucks
Flag link:
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
Bristol Myers Takes $470 Million Write-off and Scraps Orva-Cel CAR-T Program
BioSpace
Bristol-Myers Squibb
CAR-T
Orva-Cel
Flag link:
ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer
ASCO GU: Bristol Myers touts first-in-class Opdivo win in muscle-invasive bladder cancer
Fierce Pharma
ASCO GU
Bristol-Myers Squibb
Opdivo
muscle-invasive urothelial carcinoma
Flag link:
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Bristol Myers Squibb's CAR-T liso-cel wins long-delayed FDA nod
Fierce Pharma
FDA
Bristol-Myers Squibb
liso-cel
CAR-T
Flag link:
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches
Fierce Pharma
Bristol-Myers Squibb
generics
Revlimid
Zeposia
Reblozyl
Onureg
Flag link:
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
Motley Fool
Bristol-Myers Squibb
Celgene
earnings
M&A
Flag link:
Bristol Myers makes late play for COVID-19 antibody space, picking up 2 early-phase molecules from Rockefeller
Bristol Myers makes late play for COVID-19 antibody space, picking up 2 early-phase molecules from Rockefeller
Fierce Biotech
Bristol-Myers Squibb
antibodies
COVID-19
Flag link:
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Bristol Myers Squibb turns in priority review voucher for supplemental indication on an old Celgene drug
Endpoints
Bristol-Myers Squibb
Celgene
FDA
ulcerative colitis
priority review
Zeposia
Flag link:
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
Bristol Myers offloading Swiss tablet and capsule plant to Chinese CDMO WuXi STA
Fierce Pharma
Bristol-Myers Squibb
CDMO
China
WuXi Biologics
ISTA Pharmaceuticals
Flag link:

Pages